SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
Evgen Pharma PLC (EVG.L) Progress with UK and US regulators for 2022 trials
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Evgen Pharma PLC (EVG.L) Publication of data in glioblastoma cells
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
Evgen Pharma PLC (EVG.L) Early data for SFX-01 in leukaemia cell lines
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in